Jaguar Health
201 Mission Street Suite 2375
San Francisco
CA
94105
United States
Tel: 415-999-7092
Website: https://jaguar.health/
142 articles with Jaguar Health
-
Jaguar Health Set to Join Russell Microcap Index
6/23/2021
Jaguar Health, Inc. announced that Jaguar is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell.
-
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
6/11/2021
Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum.
-
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
6/2/2021
Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.p.A. founding sponsor Josh Mailman will air this Thursday, June 3, 2021, at 8:30 AM Eastern Time.
-
Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
6/1/2021
Napo EU S.p.A., the Italian subsidiary of Napo Pharmacuticals, Inc., which is a wholly owned subsidiary of Jaguar Health, Inc., provided updates on plans to pursue conditional marketing authorization from the European Medicines Agency for crofelemer, the Company's novel proprietary drug.
-
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
6/1/2021
Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities
-
Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
5/20/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea by Napo Pharmaceuticals, Inc. Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
5/19/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the Company recently launched a new social media channel for stakeholders and the Companys growing community of followers. The Jaguar Health Community Instagram page will serve as a central social media communications hub
-
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
5/18/2021
Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved
-
Jaguar Health, Inc. Reports 2021 First Quarter Financial Results
5/17/2021
First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials business updates
-
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote
5/14/2021
Jaguar Health, Inc. announced that its Annual Meeting of Stockholders held on May 13, 2021 was adjourned due to a lack of quorum.
-
Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates
5/11/2021
Jaguar Health, Inc. today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.
-
Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
4/29/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering.
-
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
4/29/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc. Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4, 2021
-
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary
4/21/2021
Jaguar Health, Inc. issued a reminder about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company, that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A., Jaguar's wholly owned Italian subsidiary.
-
Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary
4/19/2021
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the Company founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern
-
Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs
4/15/2021
Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV
-
Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting
4/14/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc.
-
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC
4/8/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment to the March 24, 2020 equity purchase agreement Equity Purchase Agreement with Oasis Capital, LLC
-
Jaguar Health Promotes Carol Lizak to Chief Financial Officer
4/6/2021
Jaguar Health, Inc. ) announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief financial officer.
-
Jaguar Health Reports 2020 Financial Results and Business Updates
3/31/2021
Jaguar Health, Inc. reported consolidated financial results for the year ended December 31, 2020.